ALK-IN-12 biochemical

ALK-IN-12

Cat. Num. AAA227510

• Purity: 98%
• Synonyms: ALK-IN-12; N/A; ALK-IN-12 biochemical

• Purity/Purification: 98%

• CAS: 1197958-53-4
• Solubility: <1mg/ml refers to the product slightly soluble or insoluble
• In vitro: ALK-IN-12 (10-50 mg/kg; orally; once daily for 13 consecutive days) shows dose-dependent antitumor activity[1]. ALK-IN-12 (3mg/kg; i.v.; 6-8 week old female CD rats) treatment shows AUC 0-infinity, CL, t 1/2 and V ss are 3039 ng/h/mL, 0.91 h/kg, 6.6 hours and 6.12 L/kg, respectively[1]. ALK-IN-12 (10 mg/kg; p.o.; 6-8 week old female CD rats) treatment shows C max, AUC 0-infinity, t max, t 1/2 and F are 3254 ng/mL, 4056 ng/h/mL, 6.0 hours, 12.5 hours and 39%, respectively[1]. Animal Model: Eight- to 10-week old female SCID/beige mice (Karpas-299 xenograft mouse model expressing the NPM-ALK fusion)[1]. Dosage: 10-50 mg/kg. Administration: Orally; once daily for 13 consecutive days. Result: Dose-dependent antitumor activity. Led to tumor stasis (50 mg/kg dose).
• Preparation and Storage: Powder: -20 degree C for 3 years; In solvent: -80 degree C for 2 years

Structure

(ABR-238901, CAS 1638200-22-2)

Structure

(ABR-238901, CAS 1638200-22-2)

Related Product Information for ALK-IN-12 biochemical

ALK-IN-12 is a potent and orally active ALK inhibitor with an IC 50 of 0.18 nM. ALK-IN-12 also inhibits IGF1R and InsR (IC 50 =20.3 and 90.6 nM). Antitumor activities.

References

1. Kim De Veirman, et al. Extracellular S100A9 Protein in Bone Marrow Supports Multiple Myeloma Survival by Stimulating Angiogenesis and Cytokine Secretion. Cancer Immunol Res. 2017 Oct;5(10):839-846.
2. Goran Marinkovi?, et al. S100A9 Links Inflammation and Repair in Myocardial Infarction. Circ Res. 2020 Aug 14;127(5):664-676.
3. A. Schiopu, et al. Short-term blockade of the S100A8/A9 alarmin in the immediate post-myocardial infarction period inhibits acute myocardial inflammation and preserves myocardial repair. European Heart Journal, Volume 38, Issue suppl_1, August 2017, ehx504.